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Abstract
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According to the amyloid hypothesis, Aβ peptides are neurotoxic and underlie development and
progression of Alzheimer’s disease (AD). Multiple Aβ clearance mechanisms, including destruction
of the peptides by proteolytic enzymes, are hypothesized to regulate physiological Aβ peptide levels.
The insulin-degrading enzyme (IDE) is considered one of the predominant enzymes having Aβ
degrading activity. Despite its putative role in protecting against AD, relatively few methods exist
for studying IDE activity in vitro. We report the application of capillary electrophoresis (CE) as a
novel method for evaluating IDE-mediated Aβ 1–40 proteolysis. This method employs chemically
unmodified substrates that are readily obtained from commercial sources. It involves minimal sample
preparation, and requires no specialized equipment beyond a CE instrument equipped with a standard
fused silica capillary. In the present analysis, we demonstrate that this CE-based method is amenable
to kinetic analysis, and show that IDE-mediated Aβ proteolysis is significantly and disproportionately
inhibited in the presence of insulin, an alternative IDE substrate.
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Amyloid beta (Aβ) peptides are short, hydrophobic peptides that can aggregate to form
neuronal plaques, which are symptomatic of Alzheimer’s disease (AD) post-mortem. Aβ
peptides are derived from the amyloid precursor protein (APP), a type I integral membrane
protein expressed within most tissues and particularly abundant within the brain (Glenner and
Wong, 1984; Tanzi et al., 1987). Posttranslational processing of APP by the β and γ-secretases
generates multiple Aβ peptide species that are subsequently released to the extracellular matrix
(Greenfield et al., 1999). Soluble Aβ peptides are normally present within human plasma and
cerebrospinal fluid, but under pathological conditions, these peptides accumulate within the
brain, due to aggregation and fibrillogenesis (Seubert et al., 1992; Shoji et al., 1992; Hardy and
Selkoe, 2002). Of the multiple Aβ peptide species, Aβ 1–40 is the most physiologically
abundant and is a principal component of neuronal plaque deposits (Sticht et al., 1995; Neve
et al., 2000).
The broadly accepted mechanism for AD progression due to neuronal Aβ accumulation has
been termed the amyloid hypothesis (Hardy and Selkoe, 2002). According to this hypothesis,
it is not the inherent toxicity of Aβ per se, but an imbalance in the production and degradation
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of these amyloidogenic peptides that leads to their neuronal accumulation, plaque formation
and resultant disease pathology. A number of biochemical strategies aimed at limiting
accumulation of Aβ have thus been pursued as potential AD therapies. Included among these
are therapies that seek to increase the rate of Aβ clearance via proteolytic degradation of the
peptide. It has been postulated that enhancement of Aβ proteolysis could decrease the amount
of peptide available for neuronal accumulation, and hence might be able to forestall, halt, or
even reverse the progression of AD (Leissring and Selkoe, 2006; Hardy and Selkoe, 2002).
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One Aβ-degrading enzyme that has received considerable biomedical attention is the insulindegrading enzyme (IDE; EC 3.4.24.56). IDE is a zinc protease with broad substrate specificity.
In addition to degrading Aβ and insulin, IDE has been shown to degrade amylin, β-endorphin,
and several other amyloidogenic peptides (Kurochkin, 2001). In animal models, partial and
complete loss of IDE function have been correlated with increased levels of Aβ and insulin,
and increased incidence of AD and type II diabetes mellitus (DM2) (Farris et al., 2003, 2004;
Miller et al., 2003). Similarly, levels of Aβ and premature death rates are significantly reduced
in a transgenic mouse AD model when IDE is overexpressed (Leissring et al., 2003a). The
various substrates of IDE can compete with one another. Substrates with higher affinity for
IDE may impair degradation of lesser affinity substrates physiologically. Consistent with this
hypothesis, insulin has been shown to function as a potent inhibitor of IDE-mediated Aβ
proteolysis (Km of 0.0657 μM vs. 1.23 μM, respectively) (Qiu et al., 1998; Farris et al.,
2005). Furthermore, an association between the frequently hyperinsulinaemic DM2 condition
and AD has been reported within human population studies (Haan, 2006; Janson et al.,
2004).
Despite significant biomedical interest in IDE-mediated Aβ proteolysis and in Aβ proteolysis
in general, relatively few methods exist for studying Aβ degradation in vitro. Assay
development has been complicated by the considerable difficulties inherent to working with
the amyloidogenic Aβ peptide, described by at least one researcher as “the peptide from
hell” (Zagorski et al., 1999). Existing methods for measuring Aβ proteolysis commonly rely
on chemically modified substrates that are difficult to obtain or synthesize. For example, one
of the most frequently cited methods used to conduct kinetic analyses of Aβ proteolysis relies
on a fluorogenic, biotinylated Aβ 1–40 derivative (Leissring et al., 2003b) that is inconsistently
available on the commercial market. Other methods used to study Aβ proteolysis have relied
upon radiolabeled substrates or indirect immunological detection methods (Qiu et al., 1998;
Vekrellis et al., 2000). These methods can be hazardous, expensive, or require careful handling
to prevent spontaneous aggregation of the peptide.
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Capillary electrophoresis (CE) has been reported as a chromatographic tool for qualitative and
quantitative studies of the Aβ peptides. CE methods have been used to measure the amount of
Aβ 1–40 present within biological fluids (Varesio et al., 2002), to evaluate the enantiomeric
condition of Aβ 1–40 (Thorsèn et al., 2001), and to better understand the aggregation process
of both Aβ 1–40 and Aβ 1–42 (Sabella et al., 2004). CE methods have thus significantly
contributed to the contemporary understanding of the biological and biochemical character of
the Aβ peptides.
We now report a CE method for evaluating IDE-mediated Aβ 1–40 proteolysis in vitro. This
method has multiple advantages over alternative techniques that have historically been used
for this purpose. It relies upon unmodified substrates that are readily obtained from multiple
commercial sources, consumes small amounts of costly experimental reagents, involves
minimal experimental preparation and handling, and requires no specialized equipment beyond
a conventional CE instrument equipped with a fused silica capillary. We have used CE to
confirm that IDE-mediated Aβ proteolysis is a progressive enzymatic process that is subject
to alternative substrate inhibition, specifically by insulin. Given the considerable interest in the
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study of Aβ proteolysis and the suitability of CE for studies of this process, we expect that the
reported method will prove to be of significant biomedical utility.
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2. Experimental
2.1. Plasmid construction
Rattus norvegicus IDE cDNA was provided by R.A. Roth (Department of Chemical and
Systems Biology, Stanford University) (Bondy et al., 1994). The rat IDE ORF corresponding
with amino acid residues M42-L1019 of the annotated protein sequence was encoded within a
pET-30b(+) expression vector to generate 6XHis-IDEM42-L1019. DNA sequencing analysis of
the selected 6XHis-IDEM42-L1019 clone revealed single base pair substitutions encoding
Y248C and E768A mutations relative to the published rat IDE sequence. Structural analysis
of the human IDE homologue reveals that these residues are positioned distal to the enzyme’s
catalytic pocket. Hence, they are not believed to have had a detrimental impact on enzyme
function.
2.2. Enzyme purification
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Plasmids encoding 6XHis-IDEM42-L1019 were transformed into expression-competent BL21
DE3 Escherichia coli, and a transformed colony was cultured under kanamycin selection.
Protein expression was induced by adding 1mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) to the media, and induction was allowed to proceed at 30 °C for approximately 3 h.
Bacterial cells were harvested by centrifugation, resuspended within lysis buffer (50mM
HEPES, 140mM NaCl, pH 7.4) containing 1 μg/ml chymostatin, leupeptin, pepstatin, and
aprotinin, and 1 mM phenylmethanesulphonylfluoride, and lysed using a chilled French
pressure cell. The cellular lysate was cleared of insoluble material by high-speed centrifugation
(100,000 g × 1 h), and filtered using a Steriflip™ 0.22 μm vacuum filter (Millipore Corp.,
Bedford, MA). Clarified lysate was subjected to immobilized nickel affinity chromatography
using an AKTAprime™ FPLC system and a HisTrap™ Fast Flow column (GE Health,
Piscathaway, NJ). Following purification, IDE was concentrated and excess imidazole
displaced by filtration using an Amicon® Ultra 100 kDa MW-cutoff filter (Millipore Corp.)
after repeated dilution with lysis buffer. The final sample was diluted to 1 mg/ml in lysis buffer
containing 20% glycerol (v/v) and stored at −80 °C.
2.3. Peptides and handling
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Recombinant human Aβ 1–40 was a gift from rPeptide, Inc. (Athens, GA). The lyophilized
peptide was treated with hexafluoroisopropanol (HFIP) to ensure an initial monomeric state in
accordance with reported methods (Dahlgren et al., 2002). After complete removal of HFIP
under a nitrogen atmosphere, the peptide was resuspended to 4 mg/ml in dimethylsulfoxide
(DMSO) and stored at −80 °C as aliquots that were thawed as needed. DMSO was chosen as
a solvent because it permitted complete solubilization of the amyloidogenic peptide but did
not affect the pH of the overall reaction mixture. Strongly acidic or basic solvents, such as
those commonly cited for resuspension of Aβ peptides (i.e., 1% NH4OH), were detrimental to
proteolysis under the weak buffering conditions of our assay. Recombinant human insulin was
obtained commercially (Sigma–Aldrich, Inc., St. Louis, MO). Lyophilized insulin was
resuspended in DMSO to 4 mg/ml. As the peptide did not immediately dissolve within this
solvent, the mixture was sonicated using a bath sonicator for approximately 5 min (Branson
Ultrasonics Corporation, Danbury, CT) until it appeared clear. Aliquots were then frozen at
−80 °C and thawed as needed.
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2.4. Preparation of buffers for analytical chromatography
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All buffers were prepared using 18 Ω nanopure deionized water. Buffers used for CE
experiments were filtered through 0.22 μm Steriflip™ or Steritop™ vacuum filters (Millipore
Corp.) prior to using. Reagents for SDS–PAGE were prepared according to standard recipes
(Sambrook et al., 1989). The background electrolyte for all CE experiments (background
electrolyte) was 100 mM potassium phosphate, pH 7.6. The buffer for all proteolysis assays
(proteolysis buffer) was 10 mM potassium phosphate, pH 7.6. This solution was prepared by
diluting the background electrolyte with water, and additionally served as the injection buffer
during CE experiments.
2.5. SDS–PAGE
Slab gel electrophoresis was conducted under denaturing conditions using a 10%
polyacrylamide gel. Proteins and peptides were detected by staining with Coomassie® Brilliant
Blue R-250. Two-fold serial dilutions of IDE were prepared in SDS–PAGE sample buffer, and
heated to 100 °C for 3 min prior to analysis. SeeBlue® Plus 2 Pre-Stained Standard (Invitrogen
Corp., San Diego, CA) was used as a size marker.
2.6. Enzymatic proteolysis
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Proteolytic assays were conducted in proteolysis buffer at 37 °C. IDE concentration was
maintained at 11 nM, and initial Aβ 1–40 concentration was 12 μM. Final reaction volume was
40 μl. Prior to mixing, thawed stocks of IDE and Aβ 1–40 were independently diluted into
proteolysis buffer to prepare 2× pre-mixtures. For insulin competition experiments, insulin was
included in the 2× Aβ 1–40 pre-mixture to twice the final reaction concentration indicated (0–
8.6 μM). 2× pre-mixtures were warmed at 37 °C for 15 min, and proteolysis was initiated by
combining enzyme and substrate(s) within a pre-warmed PCR tube that was placed in a PCR
thermocycler at a constant 37 °C. Reactions were terminated by flash freezing samples in liquid
nitrogen, and subsequently heating them to 80 °C for 3 min to inactivate IDE. Samples were
stored at −80 °C prior to evaluation by CE or HPLC. For quantitative experiments,
chromatographic peak areas were related to peptide concentration by means of a standard curve.
2.7. Standardization
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For CE experiments, a standard curve was derived using 2-fold dilutions of a 24 μM Aβ 1–40
stock solution. Dilutions were prepared in proteolysis buffer. A 12 nl portion of each sample
was analyzed by CE. The chromatographic profile of the substrate solvent, DMSO, was highly
reproducible, and did not overlap with the profiles of either the Aβ 1–40 or insulin peptides.
Thus, DMSO peak area was used as an internal standard, providing a loading control for
normalization of volume input. For HPLC experiments, a standard curve was generated by
preparing 2-fold serial dilutions of a 40 μl stock containing 5 μg Aβ 1–40, corresponding with
a maximal peptide concentration of approximately 30 μM. Each sample was loaded onto the
HPLC column in its entirety. In both instances, chromatographic peak areas observed were
graphed vs. the amount of peptide input, and standard curves generated using the 4th-order
polynomial regression function of Microsoft Excel™ (see Supplementary Figs. S1 and S2).
2.8. CE instrumentation and chromatographic conditions
All CE experiments were conducted using an Agilent G1600AX CE instrument (Agilent
Technologies Inc., Santa Clara, CA) equipped with an uncoated fused silica extended light
path capillary (55 cm eff. length, 50 μm ID). Prior to initial use, the capillary was subjected to
a series of regenerative washes for maximization of electroosmotic flow. The following rinses
were sequentially applied at ~1 bar: HPLC grade methanol × 8 min, 1 N hydrochloric acid ×
8 min, deionized water × 8 min, 0.1 N sodium hydroxide × 8 min, deionized water × 2 min,
and background electrolyte × 8 min. Between runs, capillary conditioning consisted of
J Neurosci Methods. Author manuscript; available in PMC 2010 September 2.
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sequential rinses with 0.1 N sodium hydroxide and background electrolyte, with each rinse
lasting 8 min. Prior to analysis, samples were thawed, sonicated for 10 min, and centrifuged
for 1 min at 16,000 × g. The supernatant from each sample was withdrawn and transferred to
the sample-loading carousel of the CE instrument. Sample loading onto the capillary was
achieved by a 20 mbar × 20 s pressure-controlled injection. Positive polarity electrophoretic
separation proceeded for 40 min and was regulated to a maximum current of 50 μA. A 1 min
current-regulated ramping period directly followed sample injection. The capillary cassette
was thermostated to 25 °C. During separation, analyte absorbance was measured at 200 nm
wavelength using a diode array detector. Peak area measurements were determined by
parabolic interpolation using HP 3D-CE ChemStation software. Subsequent data analysis was
performed using Microsoft Excel™, PRISM™, and Plot™ graphical analysis software.
2.9. HPLC instrumentation and chromatographic conditions
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HPLC experiments (see Supplementary data) were performed based on previously established
methods (Neuhaus et al., 1999). Reversed-phase separation of Aβ 1–40 was achieved using a
Vydac low-TFA silica-based C18 column (model 218MS54 C18, Grace Davison Discovery
Sciences, Deerfield, IL), which was heated to 60 °C under acidic conditions in the presence of
organic solvent. Separation was driven by a Rainin Dynamax solvent delivery system (model
SD-200; Rainin Instrument LLC, Oakland, CA). Data analysis was achieved using Varian
Star™ 6.4.1 graphical analysis software (Varian Inc., Walnut Creek, CA). Prior to sample
injection, samples were diluted 1:1 in 0.075% trifluoroacetic acid and 5% MeCN. During
separation, analyte absorbance was monitored at 215 nM using a UVIS-201 detection system
(PerSeptive Biosystems Inc., United Kingdom). Aβ 1–40 standard curve and proteolysis
experiments were otherwise conducted in an analogous manner to that previously described
for CE experiments, with the notable exception that samples were wholly consumed during
HPLC analysis.

3. Results and discussion
R. norvegicus IDE was isolated primarily as a single species whose apparent molecular weight
was consistent with expectations (Fig. 1). The N-terminally truncated form of rat IDE used for
this study is similar to that described in other studies of the functional enzyme (Shen et al.,
2006;Song et al., 2005). The primary IDE species comprises greater than 80% of sample input,
as judged using NIH ImageJ densitometry software. This species retains the polyhistidine tag
used for purification, as evidenced by Western blotting (Alper and Schmidt, unpublished
observation).
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Chromatographic profiles for individual components of the IDE proteolytic reaction mixture
and IDE-mediated proteolysis products were determined by CE (Fig. 2). Profile A depicts
proteolysis buffer, which was used for all CE experiments and typically contained 2.5%
DMSO. A peak attributable to DMSO passes the detection window after 20 min electrophoretic
migration time, immediately following a chromatographic trough generated by bulk flow of
the sample injection plug. Profile B depicts Aβ 1–40 as it appears in proteolysis buffer. The
characteristic trough and DMSO peak are apparent and are followed by a single new peak,
presumably Aβ, which passes the detection window after 31 min migration time. Importantly,
the area of this peak remained essentially constant between sample injections, inclusive of
samples injected up to 8 h apart, suggesting that peptide aggregation did not appreciably occur
during sample storage and processing. Profile C depicts IDE. Besides the trough and DMSO
peak, a single peak is observed that passes the detection window at 36 min migration time.
DMSO is not intrinsic to the IDE storage buffer but was included in the sample for consistency
with other profiles. Profile D depicts the components present in a reaction mixture after coincubation of IDE and Aβ 1–40 for 60 min at 37 °C. The characteristic trough, DMSO, and
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IDE peaks are present. However, the Aβ 1–40 peak expected at 31 min migration time was
nearly eliminated (see arrowhead) and has been replaced by multiple novel peaks that are
presumably reflective of the peptide degradation products. While the identity of these species
was not determined, IDE is known to cleave Aβ 1–40 at multiple sites, which have been
previously evaluated (McDermott and Gibson, 1997;Mukherjee et al., 2000). For comparison,
chromatographic profiles for components and products of the proteolytic reaction were also
determined by HPLC (Fig. S3).
Time-course experiments indicate that IDE-mediated Aβ 1–40 proteolysis is a progressive
enzymatic process (Fig. 3A). Peaks representative of intact Aβ 1–40 peptides were gradually
converted into multiple proteolytic species over the course of a 120 min proteolysis experiment.
Importantly, chromatographic profiles of the Aβ 1–40 degradation products were not observed
to overlap with those of the intact peptide species. This allowed for accurate quantification of
the amount of Aβ degradation, as inferred from the amount of Aβ remaining (Fig. 3B). A
maximal reaction velocity for IDE-mediated Aβ 1–40 proteolysis of 0.16 μmol min−1 mg−1
was observed under conditions of our assay. This value can be compared with IDE-mediated
cleavage of the synthetic fluorogenic Abz-GGFLRKGVQ-EDDnp peptide, which exhibits a
Vmax of ~0.2 μmol min−1 mg−1, and β-endorphin, which exhibits a Vmax of 2.6 μmol min−1
mg−1 (Song et al., 2001). The Aβ degradation progress curve was best fit by a 4-parameter
Boltzman sigmoidal response curve.
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IDE is capable of degrading multiple substrates, with high affinity substrates being capable of
slowing the degradation of low affinity substrates (Qiu et al., 1998). We thus examined the
utility of our CE method for evaluating such competition by including insulin in varying
amounts in our standard proteolytic reaction (Fig. 4). Aβ 1–40 proteolysis was significantly
reduced in the presence of insulin, with near to complete inhibition observed under the highest
insulin concentration evaluated. Importantly, intact insulin and Aβ 1–40 exhibited distinct
chromatographic profiles, and peaks representative of the cleavage products generated from
proteolysis of either peptide were not found to overlap to a meaningful extent with the intact
Aβ 1–40 species (Alper and Schmidt, unpublished observation). Increasing DMSO
concentrations that accompanied input of increasing amounts of insulin to the proteolysis
mixture also did not significantly affect the rate of substrate proteolysis. IDE is reported to
have significantly higher affinity for insulin than for Aβ 1–40 (Farris et al., 2005), yet, under
the conditions employed within this analysis, we observed that insulin proteolysis occurred at
a significantly slower rate than Aβ 1–40 proteolysis (maximal velocities of 0.024 and 0.16
μmol min−1 mg−1, respectively). Thus, inclusion of even small amounts of insulin in the IDE
proteolysis mixture had a disproportionate effect upon the extent of Aβ 1–40 proteolysis (Fig.
4). Observations such as ours support the hypothesis that alternative substrates can inhibit IDEmediated Aβ proteolysis, which may provide a mechanistic basis for the risk association linkage
between DM2 and AD.

4. Conclusions
We have developed a CE-based method for evaluation of IDE-mediated Aβ 1–40 proteolysis
in vitro. This method is amenable to kinetic analysis and is suitable for demonstrating the effects
of alternative substrate competition on Aβ proteolysis. In particular, we have demonstrated
that insulin strongly and disproportionately inhibits IDE-mediated Aβ 1–40 degradation. This
observation provides evidence for IDE function being central to the risk association linking
DM2 and AD, and potentially other amyloidopathies.
Our CE-based method offers significant advantages over methods that have previously been
used to study Aβ proteolysis. The method requires little specialized equipment, and relies solely
upon unmodified and commercially available substrates that are consumed in limited amounts.
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This may be contrasted with HPLC-based methods that consume greater amounts of substrate,
yet yield lower resolution, while requiring the use of specialized columns, organic solvents,
and potentially hazardous reaction components (McDermott and Gibson, 1997; Mukherjee et
al., 2000; Neuhaus et al., 1999; also see Supplementary Figs. S1–S3). For example, we estimate
that 4–11 μg of Aβ 1–40 were consumed upon sample injection during individual runs of
reported HPLC-based methods, whereas our CE-based method requires injection of less than
1 ng Aβ 1–40 per run for adequate sample detection. Comparative limitations of our CE-based
method include increased time of data collection, lack of direct sample collection, and the
potential for peak overlap, particularly among uncharged sample components.
Proteolytic processes other than IDE-mediated Aβ 1–40 and insulin degradation can likely also
be evaluated by CE with minimal modification of the current methodology. For example,
investigators seeking to study the proteolytic activity of neprilysin, another Aβ-degrading
enzyme, or those who study the degradation of amylin and other short amyloidogenic peptides
may find the reported method to be of considerable interest. Indeed, the reported method
requires only a satisfactory source of proteolytic activity, adequate analyte mobility and
detectability, and sufficiently limited peak overlap among components of the sample mixture
to permit tractable analysis.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.

Purification of recombinant IDE. Rat insulin-degrading enzyme (IDE) was heterologously
expressed in Escherichia coli as a polyhistidine-tagged protein (6XHis-IDEM42-L1019) and
purified by nickel affinity chromatography. Two-fold serial dilutions of the purified enzyme
were analyzed by SDS–PAGE and stained using Coomassie® Brilliant Blue R-250. The
leftmost sample of the dilution series contains 10 μg of total protein (lane 1). The isolated IDE
species (arrowhead) migrates in a manner consistent with its predicted molecular mass of 114
kDa.
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Fig. 2.
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IDE-mediated Aβ 1–40 proteolysis can be evaluated using CE. The components of the Aβ 1–
40 degradation reaction were evaluated alone and in combination by capillary electrophoresis
(CE). Shown are the chromatographic profiles of proteolysis buffer (A) alone, or containing
(B) 12 μM Aβ 1–40, (C) 11 nM IDE, and (D) a mixture of 12 μM Aβ 1–40 and 11 nM IDE.
The relative position of intact Aβ, had it not been degraded, is marked (arrowhead). All samples
contained 2.5% DMSO, which is responsible for the peak observed immediately after migration
of a trough caused by bulk flow of the injection plug, and were incubated at 37 °C for 60 min
prior to analysis. Chromatograms depict sample absorbance at 200 nm. Electrophoretic
migration time and sample absorbance axes have been offset between chromatograms to
facilitate data presentation.
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Fig. 3.
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CE permits kinetic analysis of IDE-mediated Aβ 1–40 proteolysis. Reaction mixtures initially
containing 12 μM Aβ 1–40 and 11 nM IDE were incubated at 37 °C over a 120 min time course.
Aliquots were removed at specific times indicated and enzyme activity was quenched.
Chromatogram traces (A) were obtained for each sample as described in Fig. 2. A standard
curve that correlates Aβ concentration with peak area was used to derive the amount of Aβ
degraded at each time point, which is depicted graphically (B). The graphical representation
of data derives from the averaged values of three experimental replicates, each having single
points for each time point condition. Error bars represent standard deviation from the mean.
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Fig. 4.

Insulin inhibits IDE-mediated Aβ 1–40 proteolysis. Reaction mixtures initially containing 12
μM Aβ 1–40 and the indicated amounts of insulin were incubated with 11 nM IDE at 37 °C
for 20 min. The quantity of Aβ 1–40 remaining was determined as described in Fig. 3, which
was used in turn to determine the amount degraded. The graphical representation of data derives
from the averaged values of four experimental replicates. Error bars represent standard
deviation from the mean values indicated.
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